HOME >> BIOLOGY >> NEWS
Rb2 gene may play role in determining effectiveness of drug therapies against breat cancer

The tumor suppressing gene pRb2/p130 may play a significant role in determining the effectiveness of drug therapies against breast cancer in women, according to a study by researchers at Temple University's Sbarro Institute for Cancer Research and Molecular Medicine.

The study, "pRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 Multimolecular Complexes Mediate the Transcription of Estrogen Receptor-a in Breast Cancer," will be presented at an international scientific lecture on Thursday, June 5, by Antonio Giordano, M.D., Ph.D., director of the Sbarro Institute. It will also be published in the June 5 issue of Oncogene (http://www.nature.com/onc/).

In the study, led by Giordano, researchers at the Sbarro Institute looked at the estrogen receptor gene alpha, which plays a crucial role in normal breast development in women and has been linked to the development and progression of mammary carcinoma, or breast cancer.

The study found that in estrogen receptor-positive and estrogen receptor-negative mammary cell lines of women who have been affected with breast cancer, pRb2/p130 binds with the estrogen receptor gene alpha and sends out signals to engage or recruit a number of molecules.

"These key molecules together are recruited by pRb2/p130 onto the receptor gene alpha, which when expressed on mammary cell lines makes the breast tumors more responsive to treatment," says Giordano, who discovered the Rb2 gene while working at Temple's Fels Cancer Institute in the early 1990s.

The researchers discovered that in estrogen receptor-negative cell lines, pRb2/p130's signal is damaged or mutated and it recruits a different sequence of molecules which cause Rb2 to silence the expression of the estrogen receptor and block drug therapies from being successful against the cancer cells.

"There is a lack of success in therapies because the drug does not recognize the tumor
'"/>

Contact: Preston M. Moretz
pmoretz@temple.edu
215-204-7476
Temple University
5-Jun-2003


Page: 1 2

Related biology news :

1. Study is another step in determining if curry can protect against Alzheimers
2. New method for determining age of artifacts fills chronological gap for scientists
3. New evidence pushes back age of sex-determining chromosomes
4. CYP17 gene proves important in determining bone growth, find University of Pittsburgh investigators
5. International study findings link acne-like rash to effectiveness of new targeted cancer treatment
6. Gene chips help gauge chemotherapys effectiveness in adult leukemia patients
7. NIH consensus panel confirms effectiveness of total knee replacement
8. Tamoxifens effectiveness may be compromised by hot flash drug
9. Drug that mimics vitamin D hormone may boost effectiveness of prostate cancer treatment
10. Antibody therapy can increase the effectiveness of cancer vaccine, early studys
11. Nutrition and exercise boost effectiveness of flu shot in older people

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/3/2020)... ... ... Brilliant , the leading smart home control and lighting company, today ... purchase in the U.S., Canada, and Puerto Rico through ADI Global Distribution, a leading ... being available for purchase through ADI’s Digital Branch , Brilliant products are now ...
(Date:9/3/2020)... ... 03, 2020 , ... Litmus Health , the research-ready ... of the company’s security practices has been completed. The assessment deemed Litmus infrastructure ... evaluation reviewed Litmus’ processes and systems, assessing them to see whether they adhere ...
(Date:8/26/2020)... ... August 24, 2020 , ... Elgia Therapeutics , a ... diseases, today announced that Dr. Stacie Canan has joined the company as its ... served as Executive Director of Global Health at Bristol Myers Squibb (formerly Celgene), ...
Breaking Biology News(10 mins):
(Date:8/7/2020)... ... August 06, 2020 , ... VGXI, a ... has closed on the purchase of greenfield for a new, expanded manufacturing facility. ... over 21 acres in the initial acquisition, with an option to purchase an ...
(Date:7/31/2020)... ... , ... R3 Stem Cell International is now offering patients the opportunity to ... total, patients may choose which extremities they would like treated. , Several studies have ... 2016). At R3 International, umbilical cord tissue is obtained from a lab with a ...
(Date:7/31/2020)... ... July 29, 2020 , ... Anomet Products has introduced new ... for use with CRM, neurostimulation, vascular, and related devices. , Anomet Medical ... requirements, performance, and cost criteria; especially where solid wire is limited. Typical configurations ...
(Date:7/31/2020)... , ... July 29, 2020 , ... ... of the top radiation centers in 16 countries, has reached its 20th anniversary ... is now in routine use at top universities including University of Pennsylvania, University ...
Breaking Biology Technology:
Cached News: